Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06991062 · ClinicalTrials.gov registry record · NA

Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHASE

A NA study of Smoking, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06991062: Recruiting NA study of Smoking, sponsored by M.D. Anderson Cancer Center.

NCT06991062 is a NA study of Smoking that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06991062, a NA study of Smoking, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn more about whether individual differences in brain responses to emotional triggers impact rTMS (repetitive transcranial magnetic stimulation) responses in people who smoke.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Conditions Studied

Interventions

  • PROCEDURE Repetitive Transcranial Magnetic Stimulation (rTMS)

Study Locations (1)

Texas

  • The University of Texas M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-02-19
Est. Completion 2028-12-01
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What NCT06991062 shows while recruiting

NCT06991062 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 454-participant average among 123 other Smoking trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 1 intervention - of which Repetitive Transcranial Magnetic Stimulation (rTMS) is the first listed.

NCT06991062 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06991062 about?

NCT06991062 is a clinical study titled "Bayesian Neurobehavioral Phenotyping: From Mechanism Identification to Personalized Neuromodulation Treatments. R61 PHASE". The goal of this clinical research study is to learn more about whether individual differences in brain responses to emotional triggers impact rTMS (repetitive transcranial magnetic stimulation) responses in people who smoke.

What is the current status of trial NCT06991062?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-02-19. Estimated completion is 2028-12-01.

What conditions does trial NCT06991062 study?

This clinical trial studies the following conditions: Smoking.

What interventions are being tested in trial NCT06991062?

The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (rTMS) (PROCEDURE).

Who is sponsoring clinical trial NCT06991062?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06991062 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06991062's enrollment target sits among peer trials

100 73rd of 123 higher than 48 of 123 other Smoking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06991062, the US trial registry maintained by the National Library of Medicine. NCT06991062 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.